Comments for The Cross-Border Biotech Blog

Comment on Friday Science Review: May 17, 2013 by Friday Science Review: May 17, 2013 « Non Resource Report

Friday Science Review: May 17, 2013 « Non Resource Report — Sat, 18 May 2013 19:47:12 +0000

[…] More: Friday Science Review: May 17, 2013 […]

Comment on Valuation and other biotech mysteries – Part 26: Some Final Thoughts by Valuation and other biotech mysteries – Part 26: Some Final Thoughts « Non Resource Report

Wed, 08 May 2013 18:42:37 +0000

[...] Link: Valuation and other biotech mysteries – Part 26: Some Final Thoughts [...]

Comment on Valuation and other biotech mysteries – Part 25: Undervalued compared to its peers? by Valuation and other biotech mysteries – Part 25: Undervalued compared to its peers? « Non Resource Report

Wed, 01 May 2013 17:48:46 +0000

[...] Read this article: Valuation and other biotech mysteries – Part 25: Undervalued compared to its peers? [...]

Comment on Friday Science Review: April 26, 2013 by Friday Science Review: April 26, 2013 « Non Resource Report

Friday Science Review: April 26, 2013 « Non Resource Report — Fri, 26 Apr 2013 16:52:42 +0000

[...] Continue reading here: Friday Science Review: April 26, 2013 [...]

Comment on Monday Deal Review: February 11, 2013 by Monday Deal Review: March 4, 2013 | The Cross-Border Biotech Blog

Monday Deal Review: March 4, 2013 | The Cross-Border Biotech Blog — Mon, 04 Mar 2013 19:23:28 +0000

[...] for the private placement of its securities which is scheduled to close this week (previously covered here). Terms of the previously announced private placement have been modified such that investors will [...]

Comment on Monday Deal Review: February 11, 2013 by Monday Deal Review: February 25, 2013 | The Cross-Border Biotech Blog

Monday Deal Review: February 25, 2013 | The Cross-Border Biotech Blog — Mon, 25 Feb 2013 12:31:26 +0000

[...] is to provide the resources necessary to conclude the merger of Trillium Therapeutics Inc. (covered here) into SCT announced February 4th, 2013 and to permit the exercise of the option by SCT to acquire [...]

Comment on Monday Deal Review: February 4, 2013 by Monday Deal Review: February 18, 2013 « The Cross-Border Biotech Blog

Monday Deal Review: February 18, 2013 « The Cross-Border Biotech Blog — Mon, 18 Feb 2013 12:31:54 +0000

[...] Inc. (CNSX: ZRO) announced that the first tranche of a private placement of units previously announced by news release on January 30, 2013 at a price of $0.15 per unit for gross proceeds of up to $600,000, has closed. The Company issued [...]

Comment on Monday Deal Review: February 4, 2013 by Monday Deal Review: February 11, 2013 « The Cross-Border Biotech Blog

Monday Deal Review: February 11, 2013 « The Cross-Border Biotech Blog — Mon, 11 Feb 2013 12:30:48 +0000

[...] Inc. (CNSX: ZRO) announced that the first tranche of a private placement of units previously announced at a price of $0.15 per unit for gross proceeds of up to $600,000, has closed. The company issued [...]

Comment on Monday Deal Review: January 21, 2013 by Monday Deal Review: February 11, 2013 « The Cross-Border Biotech Blog

Monday Deal Review: February 11, 2013 « The Cross-Border Biotech Blog — Mon, 11 Feb 2013 12:30:36 +0000

[...] TSX: YM) announced that the Supreme Court of Nova Scotia has issued a final order approving the previously announced plan of arrangement involving the company, Gilead Sciences, Inc. (Nasdaq: GILD) and 3268218 Nova [...]

Comment on Monday Deal Review: January 21, 2013 by Monday Deal Review: February 4, 2013 « The Cross-Border Biotech Blog

Monday Deal Review: February 4, 2013 « The Cross-Border Biotech Blog — Mon, 04 Feb 2013 12:30:54 +0000

[...] that, at the special meeting of shareholders of the Company the YM shareholders approved the previously announced plan of arrangement involving the company, Gilead Sciences, Inc. (Nasdaq: GILD) and 3268218 Nova [...]